On February 4, 2026, Mereo BioPharma Group Plc was sued for violations of the federal securities laws in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Mereo American Depositary Shares (“ADS”) between June 5, 2023, and December 26, 2025, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.